Pneumococcal Polysaccharide Conjugate 13-Valent

6.1 The PBAC recommended that the circumstances of listing for 13vPCV under the National Health Act 1953 for the prevention of pneumococcal disease should change. The PBAC recommended that:  The general dosing schedule move from a ‘3+0’ to a ‘2+1’ schedule with doses provided to children at around 2 and 4 months of age with a booster in the second year of life.PSD · Mar 2018

That the catch-up program should proceed as proposed, but aligned under the same principles as for routine vaccinations. That is, children who have received 3 previous doses of 13vPCV <12 months of age and present prior to 12 months of age are recommended to receive 1 further dose of 13vPCV in their second year of life with a minimum interval of 2 months after the previous dose of 13vPCV.PSD · Mar 2018

5.10 The PBAC considered ATAGI’s advice and noted the data relating to the revised dosing schedule, including the estimated reduction of IPD with the proposed change to the dosing schedule. The PBAC considered that the evidence provided supported the change to the dosing schedule, given the early waning of immunity, poorer protection in the >2 year old age groups and poorer indirect impacts on older age groups for the current dosing schedule.PSD · Mar 2018

5.12 The PBAC noted ATAGI’s advice that having a booster dose in the second year of life provided a higher immune response than having additional immunisations prior to the second year of life. The PBAC noted that ATAGI’s preferred age for the booster dose was 12 months of age to limit the duration since the 6 month dose, however the PBAC advised that in order to ensure flexibility for NIP scheduling, for the PBAC recommendation, doses would be …PSD · Mar 2018